AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7662379 — intervention group
Group type: COMPARATOR
Intervention: Carpentier‐Edwards valve
Number of subjects: 170
Study 2712403 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 ml of 0.3 M sodium citrate solution orally 5 min before induction of anaesthesia (group C)
Number of subjects: 52
Study 2712403 — intervention group
Group type: COMPARATOR
Intervention: Control group without antacids (group T)
Number of subjects: 52
Study 2560 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin (0.2 U/kg b.w.)
Number of subjects: 4
Study 2560 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromazepam (0.1 mg/kg b.w.)
Number of subjects: 4
Study 2560 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin + Bromazepam
Number of subjects: 4
Study 2560 — intervention group
Group type: COMPARATOR
Intervention: Saline (2ml)
Number of subjects: 4
Study 31630153 — intervention group
Group type: EXPERIMENTAL
Intervention: Cobitolimod
Number of subjects: 0
Study 31180866 — intervention group
Group type: EXPERIMENTAL
Intervention: RSDE (Rama torsion angle and secondary structure feature‐guided differential evolution)
Number of subjects: 28
Study 27533077 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy delivered via mail
Number of subjects: 1047
Study 25779708 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine injection
Number of subjects: 72
Study 25779708 — intervention group
Group type: COMPARATOR
Intervention: Morphine-midazolam solution
Number of subjects: 72
Study 23343906 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus (TAC) 0.1 mg/kg·day with prednisone at 0.5 mg/kg·day
Number of subjects: 33
Study 23343906 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide (CTX) 0.5-0.75 g/m(2)·month, i.v. with prednisone at 0.8 mg/kg·day
Number of subjects: 33
Study 21078629 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal 17β-oestradiol (50 µg/day)
Number of subjects: 29
Study 21078629 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 19797249 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 25 microg + bupivacaine 0.5% (0.8 ml) + normal saline 0.3 ml
Number of subjects: 70
Study 19797249 — intervention group
Group type: COMPARATOR
Intervention: Sufentanil 5 microg + bupivacaine 0.5% (0.8 ml) + normal saline 0.7 ml
Number of subjects: 70
Study 17113886 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide, 50 mg/24 hr
Number of subjects: 100
Study 17113886 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 14760143 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised complete written action plans with 2-4 action points and both inhaled corticosteroids (ICS) and oral corticosteroids (OCS)
Number of subjects: 26
Study 14760143 — intervention group
Group type: EXPERIMENTAL
Intervention: Action points based on personal best peak expiratory flow (PEF)
Number of subjects: 26
Study 14760143 — intervention group
Group type: EXPERIMENTAL
Intervention: Action points based on percentage predicted PEF
Number of subjects: 26
Study 14760143 — intervention group
Group type: EXPERIMENTAL
Intervention: Incomplete action plans
Number of subjects: 26
Study 14760143 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-specific action plans
Number of subjects: 26
Study 11313314 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon alpha2a (180 microg once weekly for 48 weeks)
Number of subjects: 33
Study 11313314 — intervention group
Group type: COMPARATOR
Intervention: Standard interferon alpha2a (thrice weekly for 48 weeks)
Number of subjects: 33
Study 11313314 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 33
Study 9150824 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure alone (E)
Number of subjects: 21
Study 9150824 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure associated with imipramine (EI)
Number of subjects: 21
Study 9150824 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy supplementing exposure (EC)
Number of subjects: 21
Study 7715641 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfractionated heparin
Number of subjects: 665
Study 7715641 — intervention group
Group type: COMPARATOR
Intervention: Low-molecular-weight heparin
Number of subjects: 665
Study 3056476 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronidase (500 U/kg given every six hours for 48 hours)
Number of subjects: 730
Study 3056476 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 730
Study 30570386 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean-style diet (MedDiet) intervention
Number of subjects: 0
Study 30570386 — intervention group
Group type: COMPARATOR
Intervention: Social group-program
Number of subjects: 0
Study 31290948 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term treatment of internet and computer game addiction (STICA)
Number of subjects: 143
Study 31290948 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control (WLC)
Number of subjects: 143
Study 28532623 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard sequential (SS) treatment: lansoprazole 30mg b.i.d. + amoxicillin 1g b.i.d. for 5 days, followed by lansoprazole 30mg b.i.d., clarithromycin 500mg b.i.d., and metronidazole 500mg t.i.d. for 5 days
Number of subjects: 280
Study 28532623 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended sequential (ES) treatment: same as SS but for 7+7 days
Number of subjects: 280
Study 28532623 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended sequential + bismuth (ES+B) treatment: same as ES but with colloidal bismuth 600mg b.i.d. for 14 days
Number of subjects: 280
Study 25672574 — intervention group
Group type: EXPERIMENTAL
Intervention: Regorafenib 160 mg once daily during the first 3 weeks of each 4-week cycle
Number of subjects: 32
Study 25672574 — intervention group
Group type: EXPERIMENTAL
Intervention: Regorafenib
Number of subjects: 32
Study 23537327 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing training
Number of subjects: 65
Study 23537327 — intervention group
Group type: COMPARATOR
Intervention: Usual care (non-trained nurses)
Number of subjects: 65
Study 21729518 — intervention group
Group type: EXPERIMENTAL
Intervention: RoTEM® analysis
Number of subjects: 60
Study 21729518 — intervention group
Group type: COMPARATOR
Intervention: Conventional coagulation tests
Number of subjects: 60
Study 18834457 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic Index (PI) based on age and mean 24 hours diastolic and systolic blood pressure.
Number of subjects: 105
Study 17209788 — intervention group
Group type: EXPERIMENTAL
Intervention: Enamel matrix derivative (EMD) treatment
Number of subjects: 30
Study 17209788 — intervention group
Group type: COMPARATOR
Intervention: Control (no EMD treatment)
Number of subjects: 30
Study 15067859 — intervention group
Group type: EXPERIMENTAL
Intervention: MF59-adjuvanted hepatitis B vaccine
Number of subjects: 100
Study 15067859 — intervention group
Group type: COMPARATOR
Intervention: Engerix-B (alum-adjuvanted yeast-derived HBV vaccine)
Number of subjects: 100
Study 10648265 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (206000 IU, 103000 IU if aged <12 mo) every 4 months
Number of subjects: 0
Study 10648265 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9054741 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrilin (highest dose)
Number of subjects: 180
Study 9054741 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study 9728228 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX) infusion of 1 mg kg‐1 h‐1 during surgery
Number of subjects: 20
Study 9728228 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PTX)
Number of subjects: 20
Study 2888474 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium
Number of subjects: 20
Study 2888474 — intervention group
Group type: COMPARATOR
Intervention: Atracurium
Number of subjects: 20
Study 31961904 — intervention group
Group type: EXPERIMENTAL
Intervention: Barbell back squatting
Number of subjects: 24
Study 31961904 — intervention group
Group type: COMPARATOR
Intervention: Standing (control)
Number of subjects: 24
Study 29185133 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise program (twice a week for 12 weeks)
Number of subjects: 41
Study 29185133 — intervention group
Group type: COMPARATOR
Intervention: Conventional drug therapy
Number of subjects: 41
Study 28901796 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-mg saxagliptin
Number of subjects: 240
Study 28901796 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study 28901796 — intervention group
Group type: COMPARATOR
Intervention: Switching from placebo to saxagliptin
Number of subjects: 240
Study 26160879 — intervention group
Group type: EXPERIMENTAL
Intervention: pomalidomide + low-dose dexamethasone
Number of subjects: 455
Study 26160879 — intervention group
Group type: COMPARATOR
Intervention: high-dose dexamethasone
Number of subjects: 455
Study 29350176 — intervention group
Group type: EXPERIMENTAL
Intervention: Prototype 4-mg nicotine lozenge
Number of subjects: 39
Study 29350176 — intervention group
Group type: EXPERIMENTAL
Intervention: Prototype III 4-mg nicotine lozenge
Number of subjects: 39
Study 29350176 — intervention group
Group type: EXPERIMENTAL
Intervention: All prototype 4-mg nicotine lozenges
Number of subjects: 39
Study 29350176 — intervention group
Group type: EXPERIMENTAL
Intervention: Prototype 4-mg nicotine lozenges
Number of subjects: 39
Study 29350176 — intervention group
Group type: COMPARATOR
Intervention: Reference 4-mg nicotine lozenge
Number of subjects: 39
Study 21978726 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg Ferric Carboxymaltose (FCM) in two doses 5 days apart
Number of subjects: 46
Study 21978726 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 21978726 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg Ferric Carboxymaltose (FCM) given on day 28
Number of subjects: 46
Study 21978726 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional 500 mg Ferric Carboxymaltose (FCM) for those not responding to initial treatment
Number of subjects: 46
Study 18644110 — intervention group
Group type: EXPERIMENTAL
Intervention: Needs-oriented discharge planning and monitoring intervention (NODPAM)
Number of subjects: 490
Study 16583234 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume-extended training for 6 months
Number of subjects: 12
Study 12672844 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemented total hip arthroplasty
Number of subjects: 98
Study 12672844 — intervention group
Group type: EXPERIMENTAL
Intervention: Cementless total hip arthroplasty
Number of subjects: 98
Study 12672844 — intervention group
Group type: COMPARATOR
Intervention: Unilateral total hip arthroplasty (cementless)
Number of subjects: 98
Study 12672844 — intervention group
Group type: COMPARATOR
Intervention: Bilateral total hip arthroplasty (one cemented, one cementless)
Number of subjects: 98
Study 12672844 — intervention group
Group type: COMPARATOR
Intervention: Cemented group (zirconia head)
Number of subjects: 98
Study 12672844 — intervention group
Group type: COMPARATOR
Intervention: Cementless group (cobalt-chromium head)
Number of subjects: 98
Study 11079086 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI-guided puncture and catheterization of the biliary system
Number of subjects: 6
Study 11079086 — intervention group
Group type: COMPARATOR
Intervention: Fluoroscopic guidance
Number of subjects: 6
Study 8730253 — intervention group
Group type: EXPERIMENTAL
Intervention: lansoprazole 30 mg b.d. for 4 weeks plus amoxycillin 1 g t.d.s. during the last 2 weeks
Number of subjects: 96
Study 8730253 — intervention group
Group type: EXPERIMENTAL
Intervention: lansoprazole 30 mg once daily for 4 weeks plus classical triple therapy (tripotassium dicitratobismuthate 240 mg b.d., amoxycillin 1 g t.d.s. and tinidazole 500 mg b.d.) for the last 2 weeks
Number of subjects: 96
Study 8730253 — intervention group
Group type: EXPERIMENTAL
Intervention: lansoprazole 30 mg once daily for 4 weeks
Number of subjects: 96
Study 1475266 — intervention group
Group type: EXPERIMENTAL
Intervention: Pall PF 30 filter
Number of subjects: 92
Study 1475266 — intervention group
Group type: COMPARATOR
Intervention: No filter (control)
Number of subjects: 92
Study 6326788 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancuronium
Number of subjects: 40
Study 6326788 — intervention group
Group type: EXPERIMENTAL
Intervention: Tubocurarine
Number of subjects: 40
Study 30067139 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorsiflexion exercise
Number of subjects: 36
Study 30067139 — intervention group
Group type: COMPARATOR
Intervention: Non-exercise group
Number of subjects: 36
Study 29084737 — intervention group
Group type: EXPERIMENTAL
Intervention: More intensive antiplatelet therapy (vorapaxar and ticagrelor pooled)
Number of subjects: 47611
Study 29084737 — intervention group
Group type: COMPARATOR
Intervention: Background antiplatelet therapy (aspirin monotherapy)
Number of subjects: 47611
Study 27401475 — intervention group
Group type: EXPERIMENTAL
Intervention: WelTel SMS intervention (interactive weekly SMS 'How are you?')
Number of subjects: 600
Study 27401475 — intervention group
Group type: EXPERIMENTAL
Intervention: WelTel SMS intervention
Number of subjects: 600
Study 27401475 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 600
Study 24527503 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 sessions of real rTMS (10 Hz, 110% of motor threshold)
Number of subjects: 108
Study 24527503 — intervention group
Group type: COMPARATOR
Intervention: 2 sessions of sham rTMS
Number of subjects: 108
Study 22648287 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic cervical facet joint injections at bilateral C5/C6 and C6/C7
Number of subjects: 400
Study 22648287 — intervention group
Group type: COMPARATOR
Intervention: Non-injection group (group N)
Number of subjects: 400
Study 20543705 — intervention group
Group type: EXPERIMENTAL
Intervention: DAILIES AquaComfort Plus for daily disposable, daily wear
Number of subjects: 83
Study 17010102 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mg G. biloba + 100 mg cilostazol
Number of subjects: 10
Study 17010102 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mg G. biloba + 75 mg clopidogrel
Number of subjects: 10
Study 17010102 — intervention group
Group type: COMPARATOR
Intervention: cilostazol
Number of subjects: 10
Study 17010102 — intervention group
Group type: COMPARATOR
Intervention: G. biloba
Number of subjects: 10
Study 17010102 — intervention group
Group type: COMPARATOR
Intervention: clopidogrel
Number of subjects: 10
Study 17010102 — intervention group
Group type: COMPARATOR
Intervention: Individual doses of cilostazol or clopidogrel
Number of subjects: 10
Study 16216721 — intervention group
Group type: EXPERIMENTAL
Intervention: Virgin argan oil (VAO) 25 ml/day
Number of subjects: 60
Study 16216721 — intervention group
Group type: COMPARATOR
Intervention: Extra virgin olive oil (EVO) 25 ml/day
Number of subjects: 60
Study 12670060 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil 5 mg/day for 28 days, then 10 mg/day thereafter
Number of subjects: 290
Study 12670060 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 290
Study 12670060 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 290
Study 10078583 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro fertilization
Number of subjects: 28
Study 10078583 — intervention group
Group type: COMPARATOR
Intervention: Ovulation induction
Number of subjects: 28
Study 7554703 — intervention group
Group type: EXPERIMENTAL
Intervention: Physostigmine (2 to 12 mg/day)
Number of subjects: 9
Study 7554703 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained low-dose steady-state intravenous infusion of physostigmine (0.5 to 25 mg/day)
Number of subjects: 9
Study 7554703 — intervention group
Group type: EXPERIMENTAL
Intervention: Single high-dose physostigmine (1 to 1.5 mg for 45 to 60 minutes)
Number of subjects: 9
Study 7554703 — intervention group
Group type: EXPERIMENTAL
Intervention: Single high-dose physostigmine
Number of subjects: 9
Study 7554703 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 9
Study 1981022 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin 20 mg twice daily
Number of subjects: 142
Study 1981022 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin 40 mg twice daily
Number of subjects: 142
Study 1981022 — intervention group
Group type: COMPARATOR
Intervention: Bendrofluazide 5 mg each morning plus placebo at night
Number of subjects: 142
Study 7265942 — intervention group
Group type: EXPERIMENTAL
Intervention: Training on relating to objects schemes
Number of subjects: 32
Study 7265942 — intervention group
Group type: EXPERIMENTAL
Intervention: Training on means-end schemes
Number of subjects: 32
Study 7265942 — intervention group
Group type: EXPERIMENTAL
Intervention: Training on both means-end and relating to objects
Number of subjects: 32
Study 7265942 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no training)
Number of subjects: 32
Study 30606197 — intervention group
Group type: EXPERIMENTAL
Intervention: eHealth intervention (webpage with monthly video clips and baby food recipes)
Number of subjects: 718
Study 30606197 — intervention group
Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 718
Study 27720706 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative mood condition
Number of subjects: 46
Study 27720706 — intervention group
Group type: COMPARATOR
Intervention: Neutral condition
Number of subjects: 46
Study 26386540 — intervention group
Group type: EXPERIMENTAL
Intervention: VGX-3100 (6 mg, intramuscularly at 0, 4, and 12 weeks)
Number of subjects: 167
Study 26386540 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1 mL, intramuscularly at 0, 4, and 12 weeks)
Number of subjects: 167
Study 26386540 — intervention group
Group type: EXPERIMENTAL
Intervention: VGX-3100
Number of subjects: 167
Study 26386540 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 167
Study 23714362 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone application intervention with a goal of 10,000 steps per day and an exercise promotion leaflet
Number of subjects: 80
Study 23714362 — intervention group
Group type: COMPARATOR
Intervention: Control group encouraged to walk an additional 30 minutes per day (equivalent to 10,000 steps) with an exercise promotion leaflet
Number of subjects: 80
Study 23714362 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone application intervention
Number of subjects: 80
Study 23714362 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study 22155910 — intervention group
Group type: EXPERIMENTAL
Intervention: FDC tablet (GPO-VIR Z30)
Number of subjects: 42
Study 22155910 — intervention group
Group type: COMPARATOR
Intervention: Liquid formulations
Number of subjects: 42
Study 22155910 — intervention group
Group type: EXPERIMENTAL
Intervention: FDC tablet (GPO-VIR Z30) in children with CYP2B 516 GG genotype
Number of subjects: 42
Study 22155910 — intervention group
Group type: EXPERIMENTAL
Intervention: FDC tablet (GPO-VIR Z30) in children with CYP2B 516 GT genotype
Number of subjects: 42
Study 22155910 — intervention group
Group type: EXPERIMENTAL
Intervention: FDC tablet (GPO-VIR Z30) in children with CYP2B 516 TT genotype
Number of subjects: 42
Study 19762048 — intervention group
Group type: EXPERIMENTAL
Intervention: TachoSil
Number of subjects: 60
Study 19762048 — intervention group
Group type: COMPARATOR
Intervention: Standard technique only
Number of subjects: 60
Study 17902128 — intervention group
Group type: EXPERIMENTAL
Intervention: HCV-positive patients
Number of subjects: 177
Study 17902128 — intervention group
Group type: COMPARATOR
Intervention: HCV-negative patients
Number of subjects: 177
Study 15657502 — intervention group
Group type: EXPERIMENTAL
Intervention: Thallium-201 (201Tl) injection of 111-130 MBq at peak exercise and a second injection of 18.5-37 MBq of 201Tl 15 min before rest images.
Number of subjects: 46
Study 15657502 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual assessment of perfusion images.
Number of subjects: 46
Study 11847938 — intervention group
Group type: EXPERIMENTAL
Intervention: brasofensine 0.5 mg
Number of subjects: 8
Study 11847938 — intervention group
Group type: EXPERIMENTAL
Intervention: brasofensine 1 mg
Number of subjects: 8
Study 11847938 — intervention group
Group type: EXPERIMENTAL
Intervention: brasofensine 2 mg
Number of subjects: 8
Study 11847938 — intervention group
Group type: EXPERIMENTAL
Intervention: brasofensine 4 mg
Number of subjects: 8
Study 11243058 — intervention group
Group type: EXPERIMENTAL
Intervention: Ready to eat (RTE) food containing 2g of Red Palm Oil (RPO)
Number of subjects: 0
Study 7476342 — intervention group
Group type: EXPERIMENTAL
Intervention: Acipimox 500 mg orally, 120 minutes before GHRH injection
Number of subjects: 13
Study 7476342 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2 tablets orally)
Number of subjects: 13
Study 7476342 — intervention group
Group type: EXPERIMENTAL
Intervention: Acipimox 500 mg orally
Number of subjects: 13
Study 2277129 — intervention group
Group type: EXPERIMENTAL
Intervention: FS 205-397 (250 mg)
Number of subjects: 161
Study 2277129 — intervention group
Group type: EXPERIMENTAL
Intervention: FS 205-397 (500 mg)
Number of subjects: 161
Study 2277129 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (650 mg)
Number of subjects: 161
Study 2277129 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 161
Study 380335 — intervention group
Group type: COMPARATOR
Intervention: Extended field radiotherapy alone
Number of subjects: 87
Study 380335 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined modality treatment (extended field radiotherapy followed by six cycles of MOPP chemotherapy)
Number of subjects: 87
Study 380335 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 87
Study 380335 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined modality therapy
Number of subjects: 87
Study 31605877 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smokers
Number of subjects: 1002
Study 31605877 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent ex-smokers
Number of subjects: 1002
Study 31605877 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term ex-smokers
Number of subjects: 1002
Study 31605877 — intervention group
Group type: EXPERIMENTAL
Intervention: Never smokers
Number of subjects: 1002
Study 31605877 — intervention group
Group type: EXPERIMENTAL
Intervention: Current and recent ex-smokers
Number of subjects: 1002